How effective is pemetinib/pemetinib in the treatment of cholangiocarcinoma?

Pemigatinib/Pemigatinib is effective in the treatment of cholangiocarcinoma, especially for patients with FGFR2 gene fusion or rearrangement. Clinical trials have shown that the drug can significantly shrink tumors or control the condition, and improve patient survival. At the same time, its safety is also good, and most side effects are controllable. This provides new treatment options for patients with cholangiocarcinoma, especially those who are unable to undergo surgery or for whom traditional chemotherapy is ineffective. However, it should be noted that genetic testing should be performed before use to ensure that the patient is suitable for it, and a doctor should be guided in the medication, pay close attention to side effects and adjust the treatment plan in a timely manner. In conclusion, pemetinib has demonstrated good efficacy and safety in the treatment of cholangiocarcinoma.